Access to highly active antiretroviral therapy (HAART) for injecting drug users in the WHO European Region 2002-2004

International Journal of Drug Policy

Volumn 18, Issue 4, 2007, Pages 271-280

  Donoghoe, Martin C ^a   Bollerup, Annemarie R ^a,b   Lazarus, Jeffrey V ^a,c   Nielsen, Stine ^a,b   Matic, Srdan ^a  

^a WORLD HEALTH ORGANIZATION   (Switzerland)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

^c LUND UNIVERSITY   (Sweden)

Author keywords

Access; Antiretroviral therapy; Europe; HIV AIDS; Injecting drug use

Indexed keywords

ANTIRETROVIRUS AGENT;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ARTICLE; DISEASE TRANSMISSION; DRUG DEPENDENCE; DRUG UTILIZATION; EASTERN EUROPE; EUROPE; HEALTH CARE ACCESS; HIGH RISK POPULATION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION PREVENTION; INJECTING DRUG USER; OPIOID SUBSTITUTION THERAPY; PATIENT COMPLIANCE; PRIORITY JOURNAL; SUBSTITUTION THERAPY; WORLD HEALTH ORGANIZATION;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; DATA COLLECTION; EUROPE; HEALTH SERVICES ACCESSIBILITY; HIV INFECTIONS; HUMANS; SUBSTANCE ABUSE, INTRAVENOUS; WORLD HEALTH ORGANIZATION;

EID: 34547140281     PISSN: 09553959     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.drugpo.2007.02.010     Document Type: Article

References (37)

1. Aceijas C., Oppenheimer E., Stimson G.V., Ashcroft R.E., Matic S., and Hickman M. Antiretroviral treatment for injecting drug users in developing and transitional countries one year before the end of the "Treating 3 million by 2005 Making it happen. The WHO strategy" (3by5). Addiction 101 (2006) 1246-1253
2. Bangsberg D.R., Hecht F.M., Clague H., Charlebois E.D., Ciccarone, Chesney M., et al. Provider assessment of adherence to HIV antiretroviral therapy. Journal of Acquired Immune Deficiency Syndromes 26 (2001) 435-442
3. Bassetti S., Battegay M., Furrer H., Rickenbach M., Flepp M., Kaiser L., et al. Why is highly active antiretroviral therapy (HAART) not prescribed or discontinued? Swiss HIV Cohort Study. Journal of Acquired Immune Deficiency Syndromes 21 (1999) 114-119
4. Bogart L.M., Kelly J.A., Catz S.L., and Sosman J.M. Impact of medical and non-medical factors on physician decision making for HIV/AIDS antiretroviral treatment. Journal of Acquired Immune Deficiency Syndromes 23 (2000) 396-404
5. Bollerup, A. R., Lazarus J., Donoghoe, M. C., Nielsen, S., & Matic S. (submitted for publication). Equity of access to highly active antiretroviral therapy (HAART) in the WHO European Region. WHO Bulletin.
6. Bollerup, A. R., Donoghoe, M. C., Lazarus J., Nielsen, S., & Matic S. (in press). Access to highly active antiretroviral therapy (HAART) in the WHO European Region 2003-2005. Scandinavian Journal of Public Health.
7. Bouhnik A.D., Chesney M., Carrieri P.M., Gallais H., Moreau J., and Moatti J.P. Non-adherence among HIV-infected injecting drug users: The impact of social instability. Journal of Acquired Immune Deficiency Syndromes 31 (2002) S149-S153
8. Bouhnik A.D., Preau M., Vincent E., Carrieri M.P., Gallais H., Lepeu G., et al. Depression and clinical progression in HIV-infected drug users treated with highly active antiretroviral therapy. Antiviral Therapy 10 (2005) 53-61
9. Carrieri M.P., Moatti J.P., Vlahov D., Obadia Y., Reynaud-Maurupt C., and Chesney M. Access to antiretroviral treatment among French HIV infected injection drug users: The influence of continued drug use. MANIF 2000 Study Group. Journal of Epidemiology and Community Health 53 (1999) 4-8
10. Celentano D.D., Vlahov D., Cohn, Shadle V.M., Obasanjo O., and Moore R.D. Self-reported antiretroviral therapy in injection drug users. Journal of the American Medical Association 280 (1999) 544-546
11. Celentano D.D., Galai N., Sethi A.K., Strathdee S.A., Vlahov D., et al. Time to initiating highly active antiretroviral therapy among HIV-infected injection drug users. AIDS 15 (2001) 1707-1715
12. Clarke S., Keenan E., Ryan M., Barry M., and Mulcahy F. Directly observed antiretroviral therapy for injection users with HIV infection. AIDS Reader 12 7 (2002) 312-316
13. Conway B., Prasad J., Reynolds R., Farley J., Jones M., Jutha S., et al. Directly observed therapy for the management of HIV-infected patients in a methadone program. Clinical Infectious Diseases 38 Suppl. (2004) S402-S408
14. Donoghoe M.C. Injecting drug use, harm reduction and HIV/AIDS. In: Matic S., Lazarus J.V., and Donoghoe M.C. (Eds). HIV/AIDS in Europe: Moving from death sentence to chronic disease management (2006), WHO Regional Office for Europe, Copenhagen 43-66
15. European Centre for the Epidemiological Monitoring of AIDS (EuroHIV). (2004). HIV/AIDS Surveillance in Europe. End-year report 2004. Saint-Maurice: Institut de Veille Sanitaire. No. 71.
16. Kohli R., Yungtai L., Howard A.A., Buono D., Floris-Moore M., Klein R.S., et al. Mortality in an urban cohort of HIV-infected and at-risk drug users in the era of highly active antiretroviral therapy. Clinical Infectious Diseases 41 (2005) 864-872
17. Lucas G.M., Cheever L.W., Chaisson R.E., and Moore R.D. Detrimental effects of continued illicit drug use on the treatment of HIV-1 infection. Journal of Acquired Immune Deficiency Syndromes 27 (2001) 251-259
18. Lucas G.M., Mullen A., Weidle P.J., Hader S., McCaul M.E., and Moore R.D. Directly administered antiretroviral therapy in methadone clinics is associated with improved HIV treatment outcomes, compared with outcomes among concurrent comparison groups. Clinical Infectious Diseases 42 (2006) 1628-1634
19. Mesquita F. Brazil: Giving IDUs access to HAART as a response to the HIV/AIDS epidemic. Breaking down barriers. Lessons on providing HIV treatment to IDUs (2004), International Harm Reduction Development (IHRD), Open Society Institute, New York
20. Moatti J.P., Carrieri M.P., Spire B., Gastaut J.A., Cassuto J.P., and Moreau J. Adherence to HAART in French HIV-infected injecting drug users: The contribution of buprenorphine drug maintenance treatment. Journal of Acquired Immune Deficiency Syndromes 14 (2000) 151-155
21. Mocroft A., Madge S., Johnson A.M., Lazzarin A., Clumeck N., Goebel F.D., et al. A comparison of exposure groups in the EuroSIDA study: Starting highly active antiretroviral therapy (HAART), response to HAART and survival. Journal of Acquired Immune Deficiency Syndromes 22 (1999) 369-378
22. Open Society Institute. Breaking down barriers. Lessons on providing HIV treatment to IDUs (2004), International Harm Reduction Development (IHRD), Open Society Institute, New York
23. Palepu A., Horton N.J., Tibbetts N., Meil S., and Samett J.H. Uptake and adherence to highly active antiretroviral therapy among HIV-infected people with alcohol and other substance use problems: The impact of substance abuse treatment. Addiction 99 (2004) 361-368
24. Poundstone K.E., Chaisson R.E., and Moore R.D. Differences in HIV disease progression by injection drug use and by sex in the era of highly active antiretroviral therapy. AIDS 15 (2001) 1115-1123
25. Regier D., Farmer M., Rae D., et al. Co-morbidity of mental disorders with alcohol and other drug abuse: Results from the Epidemiologic Catchment Area (ECA) study. Journal of the American Medical Association 264 (1990) 2511-2518
26. Sambamoorthi U., Warner L.A., Crystal S., and Walkup J. Drug abuse, methadone treatment and health services use among injection drug users with AIDS. Drug and Alcohol Dependence 60 (2000) 77-89
27. Strathdee S.A., Palepu A., Corneliesse P.G., Yip B., O'Shaughnessy M.V., Montaner J.S., et al. Barriers to use of free antiretroviral therapy in injection drug users. Journal of the American Medical Association 280 (1998) 547-549
28. Van Asten L.C., Boufassa F., Schiffer V., et al. Limited effect of highly active antiretroviral therapy among HIV-positive injecting drug users on the population level. European Journal of Public Health 13 (2003) 347-349
29. Vlahov D., and Celentano D.D. Access to highly active antiretroviral therapy for injection drug users: Adherence, resistance and death. Cadernos Saúde Pública 22 (2006) 705-731
30. WHO. WHO's contribution to universal access to HIV/AIDS prevention, care and treatment (2006), WHO, Geneva. http://www.who.int/hiv/universalaccess2010/UA2010document._en_12may06.pdf Retrieved January 29, 2007 from http://www.who.int/hiv/universalaccess2010/UA2010document._en_12may06.pdf
31. WHO, UNAIDS, and UNODC. Antiretroviral therapy and injecting drug users (2005), WHO (Evidence for Action Policy Brief WHO/HIV/2005.06), Geneva
32. Wolfe D. Paradoxes in anti-retroviral treatment for injecting drug users: Access, adherence and structural barriers in Asia and the former Soviet Union. International Journal of Drug Policy 18 (2007) 246-254
33. Wood E., Schechter M.T., Tyndall M.W., Montaner J.S., O'Shaughnessy M.V., and Hogg R.S. Antiretroviral medication use among injection drug users: Two potential futures. AIDS 14 (2000) 1229-1235
34. Wood E., Montaner J.S., Bangsberg D., Tyndall M.W., Strathdee S., O'Shaughnessy M.V., et al. Extending access to HIV antiretroviral therapy to marginalised populations in the developed world. AIDS 17 (2003) 2419-2427
35. Wood E., Montaner J.S., Yip B., Tyndall M.W., Schechter M.T., O'Shaughnessy M.V., et al. Adherence and plasma HIV RNA responses to highly active antiretroviral therapy among HIV-1 infected injection drug users. Canadian Medical Association Journal 169 7 (2003) 656-661
36. Wood E., Hogg R.S., Yip B., Dong W.W.Y., Wynhoven B., Mo T., et al. Rates of antiretroviral resistance among HIV-infected patients with and without a history of injection drug use. AIDS 19 (2005) 1189-1195
37. World Health Organization Regional Office for Europe. HIV/AIDS treatment and care for injecting drug users: Clinical protocol for the WHO European region (2006), World Health Organization Regional Office for Europe. http://www.euro.who.int/document/SHA/WHO_Chapter_5_web.pdf Retrieved January 29, 2007 from http://www.euro.who.int/document/SHA/WHO_Chapter_5_web.pdf